Economy of scales in R&D with block-busters
D. Sornette
Abstract
Are large scale research programs that include many projects more productive than smaller ones with fewer projects? This problem of economy of scale is particularly relevant for understanding recent mergers in particular in the pharmaceutical industry. We present a quantitative theory based on the characterization of distributions of discounted sales S resulting from new products. Assuming that these complementary cumulative distributions have fat tails with approximate power law structure S-a, we demonstrate that economy of scales are automatically realized when the exponent a is less than one. Empirical evidence suggests that the exponent a is approximately equal to 2/3 for the pharmaceutical industry.
Create a lesson
Related papers
Robust Golden Ratio universality as a consequence of a circulant symmetry
Luka Paljk, Johannes Schmidt, Vladislav Popkov
Replica Transition at Measurement-Altered Ising Criticality
Kabir Khanna, Sara Murciano, Romain Vasseur
Scalene Yang-Baxter triples realize all nearest-neighbour Hamiltonians with global additive symmetries
Pramod Padmanabhan, Somnath Maity, Akash Sinha et al.
Graph-theoretic framework for semi-Markov networks: transient and stationary occupation probabilities, hitting times and weak ergodicity breaking
Julian Voits
Spectral optimization of spherical lattices and applications to classical and quantum interacting spin systems
Jonas Völler, Grigorios Makris, Fabian Hassler et al.
Entropic-ordered superfluid
Isabella Zane, Andrew Lucas